NCT01334502View on ClinicalTrials.gov

Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

August 31, 2017

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

PO

DRUG

cyclophosphamide

IV

DRUG

doxorubicin hydrochloride

IV

DRUG

everolimus

PO

DRUG

prednisone

PO

DRUG

vincristine sulfate

IV

Trial Locations (1)

55905

Mayo Clinic Cancer Center, Rochester

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT01334502 - Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter